reason report
slight expect focu reduc outlook due
alari issu
bottom line expect big beat ultim
deliv modest upsid cc revenue growth
vs us op margin miss adj ep
us bigger focu lower cc revenue growth/
adj ep guidanc result impact remedi effort
anticip loss sale alari infus share
indic pre-market call listen whether
management would reiter guidanc extent beat
would bigger exclud alari impact
call start estimate dial-in password
miss ep inch help incom
benefit deliv sale beat our/consensu
y/i revenue growth cc came
cc turn busi segment rel
consensu bd life scienc cc bd intervent
cc outperform bd medic cc under-perform bd life
scienc driven bioscienc diagnost system --
aid stronger flu season bd intervent perform
led peripher intervent pi segment surgeri
under-perform urology/crit care in-lin howev
note compani reclassifi revenu associ certain
product surgeri urology/crit care pi contribut
segment result bd medic reflect strong
system growth off-set declin medic manag solut
due limit instal alari pump diabet
 gm our/consensu
higher op-ex caus ebita mgn miss vs
ultim better expect income/expens
off-set contribut upsid help adj ep beat us/
consensu
medic suppli devic
pleas refer page import disclosur price chart analyst certif
cc outlook reduc vs cc prior
reflect impact remedi effort anticip loss
sale alari infus system within bd medic reduct
mostli due lower bd medic expect flat vs prior
adj ep outlook assum headwind
alari modest vs prior fx
cc unchang intervent revenue growth cc
unchang listen call updat expect around revenue
growth driver quarterli cadenc balanc fiscal year
within busi segment given stronger flu season suspect
could provid increment tailwind life sciences/
adj ep reduc vs prior
alari lower guidanc contempl y/i cc growth
vs cc prior report growth vs
prior adj ep guidanc includ headwind relat
expir gore royalti headwind relat alari
remedi effort headwind relat tariff
fx headwind vs prior gm expect
rang vs prior ebita margin expect
rang vs impli oper
margin expans full-year tax rate interest/
net guidanc unchang
thing listen call detail around softwar
remedi effort alari -- -mgmt indic press
releas requir comprehens regulatori file expect
submit management commentari around strong flu
season expect management view potenti impact
coronaviru whether layer addit china headwind
assumpt outlook updat thought paclitaxcel drug-
coat balloon dcb market dynam qtr updat
richard newitt certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
rate price target histori becton dickinson compani
leerink place market perform rate august
creat bluematrix
pt think compar larg diversifi med-tech peer group
given exposur across medic technolog life scienc peer group includ
trade ep among group rev/ep growth profil average
correspond price-to-earnings multipl meanwhil cc revenue and/or ep growth profil
correspond price-to-earnings multipl think trade premium lower
bound rang discount upper bound appli price-to-earnings
ep get us pt
risk valuat
risk valuat includ accret estim bcr prove overli conserv aggress
fx volatil signific exposur emerg market revenue growth volatil slower-
than-anticip uptak compani diagnost bioscienc product
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
inform includ limit price quot statist obtain sourc
believ reliabl repres accur complet reli
upon inform subject chang without notic inform intend institut
use offer sell solicit buy product inform relat
svb leerink llc firm offic director employe proprietari account affili may
posit long short secur refer report and/or relat secur
time time may increas decreas posit express view contrari contain
report firm research analyst salespeopl trader profession may provid oral written
market commentari trade strategi contrari opinion express report firm
asset manag group proprietari account may make invest decis inconsist
opinion express document past perform secur guarante
predict futur perform transact strategi describ herein may suitabl investor
document may reproduc circul without svb leerink written author addit inform
avail upon request contact editori depart svb leerink llc one feder street
like firm employe research analyst receiv compens impact among factor
overal firm profit includ revenu among busi unit institut equiti
research invest bank research analyst howev compens specif
invest bank servic transact extent svb leerink research report referenc
materi either attach hereto inform compani includ price rate market
make statu price chart compens disclosur analyst certif etc avail http //
